Changes in Beneficial Ownership · 4
Tenaya Therapeutics, Inc.
TNYANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-10
- Issuer
- Tenaya Therapeutics, Inc.
- Issuer CIK
- 0001858848
- Trading symbol
- TNYA
Reporting owner 1
- Name
- Ali Faraz
- Reporting owner CIK
- 0001667937
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock[F1] | 2026-09-10[F2] | A · Form 4 | 122,000 | A | 0 | 539,782[F3] | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) | 0.6488 | 2026-09-10 | A · Form 4 | 732,500 | A | 0 | 2026-10-10[F4] | 2036-09-09 | Common Stock | 732,500 | 732,500 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.↩ 1
- F2
- The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on February 15, 2027, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested.↩ 1
- F3
- Includes 384,069 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.↩ 1
- F4
- Option granted pursuant to the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.↩ 1
Signature 1
- Signed
- /s/ Jennifer Drimmer Rokovich, Attorney in Fact
- Date
- 2026-09-11
Company context
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.